B
Bernd W. Scheithauer
Researcher at Mayo Clinic
Publications - 729
Citations - 58507
Bernd W. Scheithauer is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Adenoma & Pituitary adenoma. The author has an hindex of 119, co-authored 729 publications receiving 55985 citations. Previous affiliations of Bernd W. Scheithauer include University of North Dakota & University of Michigan.
Papers
More filters
Journal ArticleDOI
Assessment of Mitotic Activity in Pituitary Adenomas and Carcinomas.
TL;DR: The relationship between the mitotic index and biological aggressiveness of pituitary tumors was evaluated and it is suggested that when, mitotic figures are present, they do provide some indication of the behavior and invasive potential of pituitsary tumors.
Journal ArticleDOI
Interphase Cytogenetics for 1p19q and t(1;19)(q10;p10) may Distinguish Prognostically Relevant Subgroups in Extraventricular Neurocytoma
Fausto J. Rodriguez,Renan A. Mota,Bernd W. Scheithauer,Caterina Giannini,Hilary E. Blair,Kent C. New,Kevin J Wu,Dennis W. Dickson,Robert B. Jenkins +8 more
TL;DR: The results suggest that 1p19q loss and t(1;19) occur in a subset of EVN, and may be associated with aggressive histology in these tumors.
Book ChapterDOI
Pituitary adenomas in childhood and adolescence.
Journal Article
Biomarkers of Pituitary Neoplasms
TL;DR: The most common and promising biomarkers and terms were analyzed and may shed light upon the pathogenetic mechanisms and also may serve as standardized diagnostic tool for daily pathologic practice.
Journal ArticleDOI
Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation.
C. D. James,Evanthia Galanis,Lori Frederick,David W. Kimmel,Julie M. Cunningham,P. J. Atherton-Skaff,Judith R. O'Fallon,Robert B. Jenkins,Jan C. Buckner,S. B. Hunter,J. J. Olson,Bernd W. Scheithauer +11 more
TL;DR: The p53 genetic status showed no significant relationship with patient survival, and the CDKN2 and PTEN alterations were negative prognostic indicators of survival when evaluated in all 135 gliomas, but failed to predict outcome when evaluation in either of the high grade (3 or 4) tumor groups.